Combination immunotherapy treatment effective before lung cancer surgery
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
The findings, published today in Cancer Discovery, were first presented at the American Association for Cancer Research...
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly...
Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy...
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete...
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue...
Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints...
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety...
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Novel drug combinations and targeted therapies show promise for patients with leukemia
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022...
MD Anderson Research Highlights: ASH 2022 Special Edition
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides...
MD Anderson’s Christopher Flowers, M.D., receives ASH Mentor Award
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson...
MD Anderson Research Highlights: SABCS 2022 Special Edition
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...
MD Anderson Research Highlights for November 30, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson Research Highlights for November 16, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way...
MD Anderson Research Highlights: SITC 2022 Special Edition
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment...
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Hormone therapy could lower risk of immunotherapy-associated myocarditis in women
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco...
MD Anderson’s Guillermina Lozano receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of...
Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...
Some breast cancer patients with high responses to chemotherapy may not need surgery
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery...
Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center...
Allison Institute establishes internal advisory council of MD Anderson experts
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
MD Anderson and WHO establish new international collaboration to reduce women’s cancers
The University of Texas MD Anderson Cancer Center and World Health Organization (WHO) today announced a formal agreement to establish a new...
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson hosts Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022...
Lung, breast and colorectal cancer tackled in latest Texas computational oncology collaboration
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
MD Anderson and ARTIDIS announce strategic alliance to advance nanomechanical technology platform for optimizing cancer treatment
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as...
Dual-targeting CAR NK cells can prevent cell dysfunction and tumor escape
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to engineering natural killer (NK) cells with...
Dietary supplementation may improve antibiotic-induced GVHD following stem cell transplants
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression of graft-versus-host...
MD Anderson Research Highlights for September 28, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson celebrates World Cancer Research Day
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
CPRIT awards $2.5 million to support MD Anderson cancer research
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas...
MD Anderson Research Highlights for September 14, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint...
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating...
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in...
Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study
ABSTRACT 789O
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3%...
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...
MD Anderson Research Highlights: ESMO 2022 Special Edition
ABSTRACTS 735MO, 316O, 1MO, 1493MO, 457MO, 283MO, LBA68, 785O
The University of...
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development...
Swathi Arur named Emerging Leader in Health and Medicine Scholar by National Academy of Medicine
Swathi Arur, Ph.D., professor and deputy chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected as one...
MD Anderson Research Highlights for August 24, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration...
MD Anderson receives CPRIT funding to expand access to cervical cancer screening and treatment in Texas
The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research...
Allison Institute announces formation of scientific advisory board
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its scientific advisory...
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive...
MD Anderson Research Highlights for August 10, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Empyrean announce agreement to develop novel radiation therapy technologies
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development...
MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode...
MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
Cancer cells make unique form of collagen, protecting them from immune response
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome...
MD Anderson and Obsidian Therapeutics announce FDA clearance of IND application for novel TIL therapy OBX-115
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (...
Preoperative combination chemotherapy improved survival in patients with pancreatic cancer
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased...
Donna Hansel, M.D., Ph.D., to join MD Anderson as Division Head of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center today announced that Donna Hansel, M.D., Ph.D., has been named Division Head of Pathology...
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Kimberly Hoggatt Krumwiede, Ph.D., named Dean of MD Anderson’s School of Health Professions
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health...
Poziotinib is active in EGFR exon 20 mutant non-small cell lung cancer with efficacy highly dependent on insertion location
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations...
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development...
MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
MD Anderson Research Highlights for June 15, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from...
Estimating tumor-specific total mRNA level predicts cancer outcomes
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels...
MD Anderson Research Highlights: EHA 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Genetic study offers new insights into DCIS biology, progression
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson Cancer...
MD Anderson researchers present encouraging results of early-stage clinical trials at 2022 ASCO Annual Meeting
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising...
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being...
Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...
ASCO honors Eduardo Bruera, M.D., with Walther Cancer Foundation Supportive Oncology Award
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received...
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
ABSTRACT LBA7502
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free...
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy...
MD Anderson Research Highlights for June 1, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Ultrasound-guided microbubbles boost immunotherapy efficacy
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates...
MD Anderson Research Highlights: ASCO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson Research Highlights for May 18, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Adolescent and young adult leukemia survivors have shorter life span compared to those who have never had cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of...
TJ Gan, M.D., to join MD Anderson as Division Head of Anesthesiology, Critical Care and Pain Medicine
The University of Texas MD Anderson Cancer Center today announced that Tong Joo (TJ) Gan, M.D., has been named Division Head of Anesthesiology...
Targeting interleukin-6 could help relieve immunotherapy side effects
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events...
MD Anderson Research Highlights for May 4, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson and Community Health Network announce partnership to create fully integrated cancer program
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement...
MD Anderson receives over $10 million from Break Through Cancer to support collaborative research with leading cancer centers
The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working...
Vitamin E can boost immunotherapy responses by reinvigorating dendritic cells
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson...
MD Anderson Research Highlights for April 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
New platform optimizes selection of combination cancer therapies
Abstract: LB119
Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that...
Therapies targeting DNA damage response show promising antitumor activity
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor...
NK cells combined with bispecific antibody showed strong response for patients with lymphoma
Abstract: CT003
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from...
MD Anderson Research Highlights: AACR 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Lee Ellis honored by AACR for contributions to education and training in cancer research
The American Association for Cancer Research (AACR) has honored Lee Ellis, M.D., professor of Colon and Rectal Surgery at The University of...
Karen Lu honored by AACR for contributions to cancer research
The American Association for Cancer Research (AACR) has honored acclaimed investigator Karen Lu, M.D., chair of Gynecologic Oncology and Reproductive...
MD Anderson applauds Houston City Council for amending smoking ordinance to include e-cigarettes
The University of Texas MD Anderson Cancer Center applauds the unanimous vote by Houston City Council today to amend the city’s ordinance...
Distinct classes of fibroblasts in tumors play opposing roles, promoting or restraining pancreatic cancer growth
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts...
MD Anderson launches James P. Allison Institute to usher in new era for immunotherapy
The University of Texas MD Anderson Cancer Center today launched the James P. Allison Institute, a visionary research and innovation...
Novel therapy could help people with asthma, COPD, cystic fibrosis and cancer-related lung disease
A multicenter research team co-led by The University of Texas MD Anderson Cancer Center developed the first drug to treat the uncontrolled...
Neal Copeland and Nancy Jenkins elected Fellows of the AACR Academy
Neal G. Copeland, Ph.D., and Nancy A. Jenkins, Ph.D., both professors of Genetics at The University of Texas MD Anderson Cancer Center...
MD Anderson Research Highlights: SGO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
Computational approach enables spatial mapping of single-cell data within tissues
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...
Axi-cel proves effective as first-line treatment for high-risk lymphoma
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with...
MD Anderson Research Highlights for March 9, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option
Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes...
MD Anderson Research Highlights for February 23, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Newly developed radio-labeled molecule enables real-time imaging of innate immune activity
Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting...
MD Anderson receives over $31 million in CPRIT funding
The University of Texas MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of Texas (CPRIT...
MD Anderson renews partnership with Banner Health
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner...
MD Anderson Research Highlights for February 9, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson honors World Cancer Day, reinforces commitment to cancer care, prevention, research and education
The University of Texas MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...
MD Anderson Research Highlights for January 26, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson researchers elected as AAAS Fellows
In honor of their notable contributions to the field of cancer research, Juan Fueyo, M.D., and Victor Prieto, M.D., Ph.D., from The University...
MD Anderson and Yingli Pharma initiate strategic collaboration to advance development of multiple oncology programs
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology...
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles...
MD Anderson and Eisbach Bio announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...
MD Anderson Research Highlights for January 12, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Blood test helps predict who may benefit from lung cancer screening
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer...
Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free...